Allogene Therapeutics Inc

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Allogene Therapeutics reports strong Q4 performance and financial stability

Allogene Therapeutics showcased promising clinical data for its AlloCAR T therapy and emphasized a strong financial position. While facing challenges in manufacturing optimization, the company is focused on pivotal trials and cost management. Opportunities for growth include product reintroductions and ongoing program updates.

Allogene reports positive Q1 results, eyes partnerships for growth

Allogene Therapeutics showcased positive patient responses and financial prudence in Q1 2023, underlining its commitment to innovation and efficiency.
While facing resource limitations and challenges in product development, the company is exploring partnerships and expansion opportunities for future growth.
Overall, Allogene's strategic focus on patient care, operational excellence, and therapeutic advancements positions it well for continued success in the biopharmaceutical industry.

Allogene Therapeutics reports Q2 losses but showcases promising CAR-T results

Allogene Therapeutics' Q2 2023 performance reflects strategic investments in R&D and operational expenses, supported by a strong balance sheet and promising results in their allogeneic CAR-T program.
While facing challenges in patient access, manufacturing, and collaborations, the company is well-positioned to capitalize on opportunities in global expansion, next-gen technologies, and clinical trial progress.
With a focus on innovation, operational efficiency, and market expansion, Allogene Therapeutics navigates complexities in the CAR-T space to drive growth and advance its therapeutic offerings.

Allogene Therapeutics excels in Q3, poised for CAR T leadership

Allogene Therapeutics showcased strong financials, promising clinical trial results, and strategic leadership changes.
The focus on allogeneic CAR T therapy positions the company for growth and market leadership.
Challenges include competition, regulatory complexities, and ensuring manufacturing scalability.
Opportunities lie in expanding trials, presenting at key conferences, and advancing pipeline innovations.

Allogene Therapeutics reports robust financials and advances innovative therapies

Allogene Therapeutics showcased strong financials, innovative trials, and strategic partnerships, positioning the company for future growth and therapeutic advancements.
While facing challenges from external factors and clinical complexities, Allogene has opportunities to expand its therapeutic reach and enhance treatment efficacy.
Investor interest in Allogene's pipeline and the company's positive response to inquiries reflect a promising outlook for continued development and success.
Allogene's focus on cutting-edge therapies, financial stability, and community engagement underscore its commitment to advancing patient care and addressing unmet medical needs.

Allogene Therapeutics reports strong Q1 performance and eyes autoimmune expansion

Allogene Therapeutics demonstrated solid financial performance in Q1 2024, with strategic investments and a focus on core programs.
Challenges in enrollment processes, dosing strategies, and safety considerations underscore the complexities of therapeutic development.
Opportunities lie in expanding into autoimmune indications, leveraging unique treatment approaches, and impacting the CAR T treatment landscape.

Allogene Therapeutics reports Q2 momentum, faces challenges, eyes growth

Allogene Therapeutics demonstrated positive momentum and strategic planning in Q2 2024, focusing on key programs and collaborations.
While financial challenges exist, the company's strengths in manufacturing capabilities and program advancements provide a solid foundation.
Addressing challenges like differentiation in the autoimmune space and financial losses will be crucial for sustained growth.
Opportunities for growth are present in continued program progress, FDA collaborations, and strategic milestones like IND filings.

Allogene Therapeutics advances in CAR-T therapies amidst financial challenges

Allogene Therapeutics showcased promising advancements in Q3 2024 across multiple therapeutic areas, positioning itself as a key player in the CAR-T therapy space.
While financial challenges persist, the company's strong cash position and strategic focus on transformative therapies provide a solid foundation for future growth.
Addressing concerns raised by analysts regarding data, safety, and trial participation will be crucial for maintaining investor confidence and advancing clinical development.
Overall, Allogene's dedication to pioneering treatments in oncology and autoimmune diseases underscores its potential for long-term success and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharma

Alnylam Pharmaceuticals

Alexion Pharma

Horizon Pharma

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season

Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO)

SOUTH SAN FRANCISCO, Calif. and PARIS, April  29, 2020  (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international pharmaceutical company, today announced that it will have an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting being held virtually May 29 - May 31, 2020. This will be the first presentation of data from Allogene’s dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL). This study utilizes ALLO-647, Allogene's anti-CD52 monoclonal antibody (mAb) as a part of its differentiated lymphodepletion regimen.

Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

As of late, it has definitely been a great time to be an investor in Allogene Therapeutics.

Allogene's Shares March Higher, Can It Continue?

Does Allogene Therapeutics (ALLO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Allogene Therapeutics (ALLO)

Allogene Therapeutics (ALLO) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against Allogene Therapeutics (ALLO) Stock

Will Allogene Continue to Surge Higher?

Allogene Therapeutics' (ALLO) CEO David Chang on Q4 2019 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported fourth quarter and full-year 2019 financial results for the periods ended December 31, 2019.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Allogene Moves Forward With CAR-T Therapy Pipeline

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q3 2019 Results - Earnings Call Transcript

Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma   Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales

Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

SOUTH SAN FRANCISCO, Calif., Sept.  19, 2019  (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it has entered into a research collaboration agreement with Stanford University to investigate a novel nucleic acid delivery system developed by Stanford researchers to more effectively, safely and flexibly deliver intracellular RNA or DNA into lymphocytes, including T cells. Allogene intends to explore the use of this technology to advance the field of AlloCAR T therapy.

Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

SOUTH SAN FRANCISCO, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Morgan Stanley 17th Annual Global Healthcare Conference.

Allogene Therapeutics Announces September 2019 Investor Conference Schedule

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call Transcript

Collegium Pharmaceutical

Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.

News for Allogene Therapeutics Inc Stock (ALLO)